Your browser doesn't support javascript.
loading
Data sources for drug utilization research in Latin American countries-A cross-national study: DASDUR-LATAM study.
Lopes, Luciane C; Salas, Maribel; Osorio-de-Castro, Claudia Garcia Serpa; Leal, Lisiane Freitas; Doubova, Svetlana V; Cañás, Martín; Dreser, Anahi; Acosta, Angela; Baldoni, Andre Oliveira; de Cássia Bergamaschi, Cristiane; Mota, Daniel Marques; Gómez-Galicia, Diana L; Sepúlveda-Viveros, Dino; Delgado, Edgard Narvaez; da Costa Lima, Elisangela; Chandia, Felipe Vera; Ferre, Felipe; Marin, Gustavo H; Olmos, Ismael; Zimmermann, Ivan R; Fulone, Izabela; Roldán-Saelzer, Juan; Sánchez-Salgado, Juan Carlos; Castro-Pastrana, Lucila I; de Souza, Luiz Jupiter Carneiro; Beltrán, Manuel Machado; Silva, Marcus Tolentino; Mena, María Belén; de França Fonteles, Marta Maria; Urtasun, Martín A; Tarapués, Mónica; Hernández, Patricia Granja; Medero, Natalia; Herrera-Comoglio, Raquel; Barberato-Filho, Silvio; Galvão, Taís Freire; Luiza, Vera Lucia; Santa-Ana-Tellez, Yared; Rodríguez-Tanta, Yesenia; Elseviers, Monique.
Afiliação
  • Lopes LC; Pharmaceutical Science Graduate Course, University of Sorocaba, Sorocaba, Brazil.
  • Salas M; Epidemiology, Cardiovascular, Clinical Safety and Pharmacovigilance, Daiichi Sankyo, Inc., Basking Ridge, USA.
  • Osorio-de-Castro CGS; CCEB/CPeRT, University of Pennsylvania Perelman School of Medicine, Philadelphia, USA.
  • Leal LF; Department of Medicines Policy and Pharmaceutical Services, Sergio Arouca National School of Public Health, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil.
  • Doubova SV; Department of Epidemiology Biostatistics and Occupational Health, McGill University/Centre for Clinical Epidemiology - Lady Davis Institute, Montreal, Canada.
  • Cañás M; Epidemiology and Health Services Research Unit CMN Siglo XXI, Mexican Institute of Social Security, Mexico City, Mexico.
  • Dreser A; Institute of Health Sciences, Arturo Jauretche National University, Florencio Varela, Argentina.
  • Acosta A; Federación Médica de la Provincia de Buenos Aires, FEMEBA, La Plata, Argentina.
  • Baldoni AO; Centre for Health Systems Research, National Institute of Public Health, Cuernavaca, Mexico.
  • de Cássia Bergamaschi C; Departamento de Ciencias Farmacéuticas, Facultad de Ciencias Naturales, Universidad ICESI, Cali, Colombia.
  • Mota DM; Pharmaceutical Science Course, Federal University of São João Del-Rei, Divinópolis, Brazil.
  • Gómez-Galicia DL; Pharmaceutical Science Graduate Course, University of Sorocaba, Sorocaba, Brazil.
  • Sepúlveda-Viveros D; Fifth Board of Directors, Brazilian Health Regulatory Agency - ANVISA, Brasilia, Brazil.
  • Delgado EN; PITC - Pharmacy of Faculty, Autonomous University of the State of Morelos, Cuernavaca, Mexico.
  • da Costa Lima E; School of Medicine, Autonomous University of Chile, Santiago, Chile.
  • Chandia FV; Public Health, Self-employed, Managua, Nicaragua.
  • Ferre F; School of Pharmacy, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
  • Marin GH; Health Technology Assessment Unit, Pontifical Catholic University of Chile, Santiago, Chile.
  • Olmos I; School of Medicine, Federal University of Minas Gerais, Belo Horizonte, Brazil.
  • Zimmermann IR; Faculty of Medicine, National University of La Plata - CONICET, La Plata, Argentina.
  • Fulone I; Unit of Clinical Pharmacology - Vilardebó Hospital, ASSE - State Health Services Administration, Montevidéu, Uruguay.
  • Roldán-Saelzer J; Department of Public Health, University of Brasilia, Brasilia, Brazil.
  • Sánchez-Salgado JC; Pharmaceutical Science Graduate Course, University of Sorocaba, Sorocaba, Brazil.
  • Castro-Pastrana LI; Pharmacovigilance Subdepartment, of the Department National Medicines Agency, Institute of Public Health of Chile, Santiago, Chile.
  • de Souza LJC; Scientific Department, Hypermedic MX, Mexico City, Mexico.
  • Beltrán MM; Department of Chemical and Biological Sciences, University of the Americas Puebla, Cholula, Mexico.
  • Silva MT; Research and Development, Oswaldo Cruz Foundation (Ministry of Health), Brasilia, Brazil.
  • Mena MB; Pharmaceutical Science, National University of Colombia, Bogota, Colombia.
  • de França Fonteles MM; Pharmaceutical Science Graduate Course, University of Sorocaba, Sorocaba, Brazil.
  • Urtasun MA; Faculty of Medical Sciences, Central University of Ecuador, Quito, Ecuador.
  • Tarapués M; Technological Development and Innovation in Medicines Graduate Course, Federal University of Ceara, Fortaleza, Brazil.
  • Hernández PG; Institute of Health Sciences, Arturo Jauretche National University, Florencio Varela, Argentina.
  • Medero N; Federación Médica de la Provincia de Buenos Aires, FEMEBA, La Plata, Argentina.
  • Herrera-Comoglio R; Faculty of Medical Sciences, Central University of Ecuador, Quito, Ecuador.
  • Barberato-Filho S; Humanistic Organization for Social Change, HIVOS, Quito, Ecuador.
  • Galvão TF; Unit of Clinical Pharmacology - Vilardebó Hospital, ASSE - State Health Services Administration, Montevidéu, Uruguay.
  • Luiza VL; School of Medical Sciences, National University of Cordoba, Córdoba, Argentina.
  • Santa-Ana-Tellez Y; Pharmaceutical Science Graduate Course, University of Sorocaba, Sorocaba, Brazil.
  • Rodríguez-Tanta Y; School of Pharmaceutical Sciences, University of Campinas, Campinas, Brazil.
  • Elseviers M; Department of Medicines Policy and Pharmaceutical Services, Sergio Arouca National School of Public Health, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil.
Pharmacoepidemiol Drug Saf ; 31(3): 343-352, 2022 03.
Article em En | MEDLINE | ID: mdl-34957616
ABSTRACT

PURPOSE:

Drug utilization research (DUR) contributes to inform policymaking and to strengthen health systems. The availability of data sources is the first step for conducting DUR. However, documents that systematize these data sources in Latin American (LatAm) countries are not known. We compiled the potential data sources for DUR in the LatAm region.

METHODS:

A network of DUR experts from nine LatAm countries was assembled and experts conducted (i) a website search of the government, academic, and private health institutions; (ii) screening of eligible data sources, and (iii) liaising with national experts in pharmacoepidemiology (via an online survey). The data sources were characterized by accessibility, geographic granularity, setting, sector of the data, sources and type of the data. Descriptive analyses were performed.

RESULTS:

We identified 125 data sources for DUR in nine LatAm countries. Thirty-eight (30%) of them were publicly and conveniently available; 89 (71%) were accessible with limitations, and 18 (14%) were not accessible or lacked clear rules for data access. From the 125 data sources, 76 (61%) were from the public sector only; 46 (37%) were from pharmacy records; 43 (34%) came from ambulatory settings and; 85 (68%) gave access to individual patient-level data.

CONCLUSIONS:

Although multiple sources for DUR are available in LatAm countries, the accessibility is a major challenge. The procedures for accessing DUR data should be transparent, feasible, affordable, and protocol-driven. This inventory could permit a comparison of drug utilization between countries identifying potential medication-related problems that need further exploration.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Armazenamento e Recuperação da Informação / Uso de Medicamentos Limite: Humans Idioma: En Revista: Pharmacoepidemiol Drug Saf Assunto da revista: EPIDEMIOLOGIA / TERAPIA POR MEDICAMENTOS Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Brasil

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Armazenamento e Recuperação da Informação / Uso de Medicamentos Limite: Humans Idioma: En Revista: Pharmacoepidemiol Drug Saf Assunto da revista: EPIDEMIOLOGIA / TERAPIA POR MEDICAMENTOS Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Brasil
...